Citi analyst Yigal Nochomovitz raised the firm’s price target on Alpha Tau (DRTS) to $9 from $7 and keeps a Buy rating on the shares. The firm believes the company’s radiopharma platform is being underappreciated at current share levels. Alpha Tau’s “broader-than-expected” Japan approval in head and neck cancer is leading to partnership opportunities, the analyst tells investors in a research note.
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
